Copyright
©The Author(s) 2022.
World J Gastrointest Endosc. Sep 16, 2022; 14(9): 536-546
Published online Sep 16, 2022. doi: 10.4253/wjge.v14.i9.536
Published online Sep 16, 2022. doi: 10.4253/wjge.v14.i9.536
Table 1 Patient characteristics and treatment
| Parameter | |
| Total patients, n | 43 |
| Unresectable or treated in other hospitals, n | 9 |
| Underwent resection, n | 34 |
| Age, yr (mean ± standard deviation) | 68.0 ± 11.1 |
| Sex, n (male/female) | 20/14 |
| UICC stage 8th edition, n | |
| I | 16 |
| II | 8 |
| III | 10 |
| Patients already having biliary stents, n | 4 |
| Treatment, n | |
| Endoscopic ampullectomy | 9 |
| Surgery | 25 |
| Hilar biliary invasion, n | 0 |
| Local recurrence, n | 0 |
Table 2 Adverse events of treatment
| Adverse event | n |
| Post-endoscopic ampullectomy bleeding | |
| Mild | 0 |
| Moderate | 2 |
| Severe | 0 |
| Post-ERC pancreatitis | |
| Mild | 0 |
| Moderate | 3 |
| Severe | 0 |
- Citation: Takagi T, Sugimoto M, Suzuki R, Konno N, Asama H, Sato Y, Irie H, Nakamura J, Takasumi M, Hashimoto M, Kato T, Kobashi R, Yanagita T, Hashimoto Y, Marubashi S, Hikichi T, Ohira H. Screening for hilar biliary invasion in ampullary cancer patients. World J Gastrointest Endosc 2022; 14(9): 536-546
- URL: https://www.wjgnet.com/1948-5190/full/v14/i9/536.htm
- DOI: https://dx.doi.org/10.4253/wjge.v14.i9.536